Article Title：The 100 most cited articles in malignant hyperthermia

Journal Name：Anesthesiology and Perioperative Science

Author Names： Yongzheng Han [1#], Yinyin Qu [1#], Xiaoxiao Wang [2], Yang Zhou [1], Lukun Yang [3], Haiming Du [1], Jing Zhang [1], Yandong Jiang [4], Zhengqian Li [1*], Xiangyang Guo [1*]

Affiliation And E-Mail Address Of The Corresponding Author：

Zhengqian Li, Department of Anesthesiology, Peking University Third Hospital, Beijing, China. Tel: +86-10-82267272. E-mail: zhengqianli@bjmu.edu.cn.

Xiangyang Guo, Department of Anesthesiology, Peking University Third Hospital, Beijing, China. Tel: +86-10-82267276. E-mail: puthmzk@hsc.pku.edu.cn.

Table S1 List of the top 100 most cited articles in malignant hyperthermia (1900-2023)

Rank	Author	Article	Country	Citation	ACR	IF	JCI
1	Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VK, Weiler JE, O'Brien PJ, MacLennan DH.	Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science. 1991,253(5018):448-451.	Canada	1254	40.5	63.832	10.15
2	Gronert GA	Gronert GA. Malignant hyperthermia. Anesthesiology. 1980,53(5):395-423.	United States	553	13.2	9.198	2.84
3	MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG.	Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990,43(6258):559-561.	Canada	483	15.1	69.504	10.86
4	Britt BA, Kalow W.	Malignant hyperthermia: a statistical review. Canadian Anaesthetists Society Journal. 1970,17(4):293-315.	Canada	430	8.3	6.713	1.66
5	MacLennan DH, Phillips MS.	Malignant hyperthermia. Science. 1992,256(5058):789-794.	Canada	401	13.4	69.832	10.15
6	McCarthy TV, Healy JM, Heffron JJ, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K.	Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 1990,343(6258):562-564.	Ireland, Germany, England	371	11.6	69.504	10.86
7	Kalow W, Britt BA, Terreau ME, Haist C.	Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970,2(7679):895-898.	Canada	356	6.8	202.731	21.87
8	Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ.	A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994,80(4):771-779.	United States, Canada, Australia, England, Denmark	354	12.6	9.198	2.84
9	Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F.	Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004,59(4):364-373.	Germany	349	19.4	12.893	3.03
10	Ellis FR, Halsall PJ, Ording H, Fletcher R, Rankkley E, Heffron JJA, Lehane M, Mortier W, Steinbereitner K, Sporn P, Theunynck D, Verburg R.	A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. British Journal of Anaesthesia. 1984,56(11):1267-1269.	England, Denmark, Sweden, Ireland, Germany, Austria, France, Netherlands	343	9.0	11.719	2.63
11	Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P.	Mutations in RYR1 in malignant hyperthermia and central core disease. Human Mutation. 2006,27(10):977-989.	England	341	21.3	4.7	1.06
12	Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD.	Anaesthetic deaths in a family. British Journal of Anaesthesia. 1962,34:395-396.	Australia	319	5.3	11.719	2.63
13	Monnier N, Procaccio V, Stieglitz P, Lunardi J.	Malignant-hyperthermia susceptibility is associated with a mutation of the α1-subunit of the human dihydropyridine-	France	295	11.8	11.043	2.52

		sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. American Journal of Human Genetics. 1997,60(6):1316-1325.					
14	Rosenberg H, Davis M, James D, Pollock N, Stowell K.	Malignant hyperthermia. Orphanet Journal of Rare Diseases. 2007,2:21.	United States	290	19.3	4.302	0.83
15	Quane KA, Healy JM, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ording H, Bendixen D, Mortier W, Linz U, Muller CR, McCarthy TV.	Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genetics. 1993,5(1):51-55.	Ireland, Italy, Norway, Denmark, Germany	285	9.8	41.376	8.77
16	Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K.	Malignant hyperthermia: a review. Orphanet Journal of Rare Diseases. 2015,10:93.	United States, New Zealand	263	37.6	4.302	0.83
17	McCarthy TV, Quane KA, Lynch PJ.	Ryanodine receptor mutations in malignant hyperthermia and central core disease. Human Mutation. 2000,15(5):410-417.	Ireland	263	12.0	4.7	1.06
18	Durham WJ, Aracena-Parks P, Long C, Rossi AE, Goonasekera SA, Boncompagni S, Galvan DL, Gilman CP, Baker MR, Shirokova N, Protasi F, Dirksen R, Hamilton SL.	RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell. 2008,133(1):53-65.	United States, Italy	252	18.0	66.85	8.92
19	Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF.	Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. Journal of Biological Chemistry. 1988,263(19):9310-9315.	United States	247	7.3	5.485	0.91
20	Mickelson JR, Louis CF.	Malignant hyperthermia: excitation-contraction coupling, Ca^{2+} release channel, and cell Ca^{2+} regulation defects. Physiological Reviews. 1996,76(2):537-592.	United States	242	9.3	46.513	4.58
21	Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F.	In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiologica Scandinavica. 1997,41(8):955-966.	Italy, England, Israel, Germany, Ireland, Belgium, France, Austria, Sweden, Iceland, Netherlands, Switzerland	240	9.6	2.274	0.72
22	Zhao F, Li P, Chen SR, Louis CF, Fruen BR.	Dantrolene inhibition of ryanodine receptor Ca^{2+} release channels. Molecular mechanism and isoform selectivity. Journal of Biological Chemistry. 2001,276(17):13810-13816.	United States, Canada	238	11.3	5.485	0.91
23	Harrison GG.	Control of the malignant hyperpyrexic syndrome in MHS	South Africa	227	4.8	11.719	2.63

		swine by dantrolene sodium. British Journal of Anaesthesia. 1975,47(1):62-65.					
24	Ward A, Chaffman MO, Sorkin EM.	Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs. 1986,32(2):130-168.	New Zealand	221	6.1	11.431	2.24
25	Kolb ME, Horne ML, Martz R.	Dantrolene in human malignant hyperthermia. Anesthesiology. 1982,56(4):254-262.	United States	217	5.4	9.198	2.84
26	Jurkat-Rott K, McCarthy T, Lehmann-Horn F.	Genetics and pathogenesis of malignant hyperthermia. Muscle & Nerve. 2000,23(1):4-17.	Germany, Ireland	207	9.4	3.852	0.75
27	Tong J, Oyamada H, Demaurex N, Grinstein S, McCarthy TV, MacLennan DH.	Caffeine and halothane sensitivity of intracellular Ca^{2+} release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. Journal of Biological Chemistry. 1997,272(42):26332-26339.	Canada, Ireland	195	7.8	5.485	0.91
28	Britt BA, Locher WG, Kalow W.	Hereditary aspects of malignant hyperthermia. Canadian Anaesthetists Society Journal. 1969,16(2):89-98.	Canada, United States	178	3.4	6.713	1.66
29	Denborough M.	Malignant hyperthermia. Lancet. 1998,352(9134):1131-1136.	Australia	175	7.3	202.731	21.87
30	Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB.	Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesthesia and Analgesia. 2010,110(2):498-507.	United States	174	14.5	6.627	1.95
31	Endo M, Yagi S, Ishizuka T, Horiuti K, Koga Y, Amaha K.	Changes in the calcium induced calcium release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia. Biomedical Research-Tokyo. 1983,4(1):83-92.	Japan	164	4.2	2.964	0.31
32	Harrison GG, Saunders SJ, Biebuyck JF, Hickman R, Dent DM, Weaver V, Terblanche J.	Anaesthetic-induced malignant hyperpyrexia and a method for its prediction. British Journal of Anaesthesia. 1969,41(10):844-855.	South Africa	164	3.1	11.719	2.63
33	Urwyler A, Deufel T, McCarthy T, West S.	Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. British Journal of Anaesthesia. 2001,86(2):283-287.	Switzerland, Germany, Ireland, England	159	7.6	11.719	2.63
34	Fruen BR, Mickelson JR, Louis CF.	Dantrolene inhibition of sarcoplasmic reticulum Ca^{2+} release by direct and specific action at skeletal muscle ryanodine receptors. Journal of Biological Chemistry. 1997,272(43):26965-26971.	United States	158	6.3	5.485	0.91
35	Otsu K, Khanna VK, Archibald AL, MacLennan DH.	Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine	Canada, England	154	5.0	4.31	1.21

		receptor gene in backcross families. Genomics. 1991,11(3):744-750.					
36	Loke J, MacLennan DH.	Malignant hyperthermia and central core disease: disorders of Ca^{2+} release channels. American Journal of Medicine. 1998,104(5):470-486.	Canada	153	6.4	5.928	1.01
37	Tong J, McCarthy TV, MacLennan DH.	Measurement of resting cytosolic Ca^{2+} concentrations and Ca^{2+} store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca^{2+} release channels. Journal of Biological Chemistry. 1999,274(2):693-702.	Canada, Ireland	152	6.6	5.485	0.91
38	Ohnishi ST, Taylor S, Gronert GA.	Calcium-induced Ca^{2+} release from sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. The effects of halothane and dantrolene. Febs Letters. 1983,161(1):103-107.	United States	152	3.9	3.864	0.54
39	Fill M, Coronado R, Mickelson JR, Vilven J, Ma JJ, Jacobson BA, Louis CF.	Abnormal ryanodine receptor channels in malignant hyperthermia. Biophysical Journal. 1990,57(3):471-475.	United States	149	4.7	3.699	0.88
40	Gillard EF, Otsu K, Fujii J, Duff C, de Leon S, Khanna VK, Britt BA, Worton RG, MacLennan DH.	Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics. 1992,13(4):1247-1254.	Canada	146	4.9	4.31	1.21
41	Britt BA.	Etiology and pathophysiology of malignant hyperthermia. Federation Proceedings. 1979,38(1):44-48.	Canada	142	3.3	NA	NA
42	Allen GC, Larach MG, Kunselman AR.	The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. Anesthesiology. 1998,88(3):579-588.	United States	141	5.9	9.198	2.84
43	Ording H.	Incidence of malignant hyperthermia in Denmark. Anesthesia and Analgesia. 1985,64(7):700-704.	Denmark	141	3.8	6.627	1.95
44	Moulds RF, Denborough MA.	Biochemical basis of malignant hyperpyrexia. British Medical Journal. 1974,2(5913):241-244.	Australia	140	2.9	17.215	7.15
45	Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J.	Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology. 2002,97(5):1067-1074.	France	138	6.9	9.198	2.84
46	Hopkins PM.	Malignant hyperthermia: advances in clinical management and diagnosis. British Journal of Anaesthesia. 2000,85(1):118-128.	England	137	6.2	11.719	2.63
47	Mitchell G, Heffron JJ.	Porcine stress syndromes. Advances in Food Research. 1982,28:167-230.	United States	137	3.4	NA	NA

48	Iles DE, Lehmann-Horn F, Scherer SW, Tsui LC, Olde Weghuis D, Suijkerbuijk RF, Heytens L, Mikala G, Schwartz A, Ellis FR, Stewart AD, Deufel T, Wieringa B.	Localization of the gene encoding the α2/δ-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Human Molecular Genetics. 1994,3(6):969-975.	Netherlands, Germany, Canada, Belgium, United States, England	136	4.9	5.121	1.12
49	Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, Xu X, Uchinoumi H, Okuda S, Yamamoto T, Koseki N, Kyushiki H, Ikemoto N, Matsuzaki M..	Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. Journal of the American College of Cardiology. 2009,53(21):1993-2005.	Japan, United States	135	10.4	27.206	4.74
50	Chelu MG, Goonasekera SA, Durham WJ, Tang W, Lueck JD, Riehl J, Pessah IN, Zhang P, Bhattacharjee MB, Dirksen RT, Hamilton SL.	Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. Faseb Journal. 2006,20(2):329-330.	United States	133	8.3	5.834	0.98
51	Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, Matschke J, Schulte Am Esch J.	Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology. 2001,94(1):95-100.	Germany	133	6.3	9.198	2.84
52	Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg EJ, Drost G, Quinlivan R, Snoeck M, Norwood F, Radunovic A, Straub V, Roberts M, Vrancken AF, van der Pol WL, de Coo RI, Manzur AY, Yau S, Abbs S, King A, Lammens M, Hopkins PM, Mohammed S, Treves S, Muntoni F, Wraige E, Davis MR, van Engelen B, Jungbluth H.	Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscular Disorders. 2013,23(7):540-548.	England, Netherlands, Australia	132	14.7	3.538	0.86
53	King JO, Denborough MA, Zapf PW.	Inheritance of malignant hyperpyrexia. Lancet. 1972,1(7746):365-370.	Australia	127	2.5	202.731	21.87
54	Hopkins PM.	Malignant hyperthermia: pharmacology of triggering. British Journal of Anaesthesia. 2011,107(1):48-56.	England	122	11.1	11.719	2.63
55	Quane KA, Keating KE, Manning BM, Healy JM, Monsieurs K, Heffron JJ, Lehane M, Heytens L, Krivosic-Horber R, Adnet P, Ellis FR, Monnler N, Lunardl J, McCarthy TV.	Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Human Molecular Genetics. 1994,3(3):471-476.	Ireland, Belgium, France, England	121	4.3	5.121	1.12
56	Britt BA, Kalow W, Gordon A, Humphrey JG, Rewcastle NB.	Malignant hyperthermia: an investigation of five patients. Candian Anaesthetists Society Journal. 1973,20(4):431-467.	Canada	121	2.5	6.713	1.66
57	Denborough MA, Ebeling P, King JO,	Myopathy and malignant hyperpyrexia. Lancet.	Australia	121	2.3	202.731	21.87

	Zapf P.	1970,1(7657):1138-1140.					
58	Lopez JR, Alamo L, Caputo C, Wikinski J, Ledezma D.	Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle & Nerve. 1985,8(5):355-358.	Venezuela	120	3.2	3.852	0.75
59	Saidman LJ, Havard ES, Eger EI.	Hyperthermia during anesthesia. Jama. 1964,190:1029-1032.	United States	118	2.0	157.375	10.46
60	Kim DH, Sreter FA, Ohnishi ST, Ryan JF, Roberts J, Allen PD, Meszaros LG, Antoniu B, Ikemoto N.	Kinetic studies of Ca^{2+} release from sarcoplasmic reticulum of normal and malignant hyperthermia susceptible pig muscles. Biochimica et Biophysica Acta. 1984,775(3):320-327.	United States	117	3.1	NA	NA
61	Hopkins PM, Ruffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, Müller CR, Urwyler A.	European Malignant Hyperthermia Group. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. British Journal of Anaesthesia. 2015,115(4):531-539.	England, Germany, Netherlands, Switzerland, Denmark	116	16.6	11.719	2.63
62	Nelson TE, Flewellen EH.	Current concepts. The malignant hyperthermia syndrome. New England Journal of Medicine. 1983,309(7):416-418.	United States	115	2.9	176.082	22.47
63	Gronert GA, Theye RA.	Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes. Anesthesiology. 1976,44(1):36-43.	United States	115	2.5	9.198	2.84
64	Lucke JN, Hall GM, Lister D.	Porcine malignant hyperthermia. I: Metabolic and physiological changes. British Journal of Anaesthesia. 1976,48(4):297-304.	England	114	2.5	11.719	2.63
65	Britt BA, Kalow W.	Malignant hyperthermia: aetiology unknown. Candian Anaesthetists Society Journal. 1970,17(4):316-330.	Canada	113	2.2	6.713	1.66
66	Levitt RC, Olckers A, Meyers S, Fletcher JE, Rosenberg H, Isaacs H, Meyers DA.	Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics. 1992,14(3):562-526.	United States, South Africa	112	3.7	4.31	1.21
67	Smith C, Bampton PR.	Inheritance of reaction to halothane anaesthesia in pigs. Genetics Research. 1977,29(3):287-292.	England	112	2.5	1.375	0.22
68	Sudbrak R, Procaccio V, Klausnitzer M, Curran JL, Monsieurs K, van Broeckhoven C, Ellis R, Heyetens L, Hartung EJ, Kozak-Ribbens G,.	Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. American Journal of Human Genetics. 1995,56(3):684-691.	Germany, France, England, Belgium, Austria	111	4.1	11.043	2.52
69	Ledbetter MW, Preiner JK, Louis CF, Mickelson JR.	Tissue distribution of ryanodine receptor isoforms and alleles determined by reverse transcription polymerase chain reaction. Journal of Biological Chemistry. 1994,269(50):31544-31551.	United States	111	4.0	5.485	0.91
70	Glahn KP, Ellis FR, Halsall PJ, Muller CR, Snoeck MM, Urwyler A, Wappler F.	Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant	Denmark, England, Germany, Netherlands,	110	9.2	11.719	2.63

		Hyperthermia Group. British Journal of Anaesthesia. 2010,105(4):417-420.	Switzerland				
71	Manning BM, Quane KA, Ording H, Urwyler A, Tegazzin V, Lehane M, O'Halloran J, Hartung E, Giblin LM, Lynch PJ, Vaughan P, Censier K, Bendixen D, Comi G, Heytens L, Monsieurs K, Fagerlund T, Wolz W, Heffron JJ, Muller CR, McCarthy TV.	Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. American Journal of Human Genetics. 1998,62(3):599-609.	Ireland, Denmark, Switzerland, Italy, Germany, Belgium, Norway	110	4.6	11.043	2.52
72	Davies W, Harbitz I, Fries R, Stranzinger G, Hauge JG.	Porcine malignant hyperthermia carrier detection and chromosomal assignment using a linked probe. Animal Genetics. 1988,19(3):203-212.	Switzerland	110	4.6	2.884	0.89
73	Harrison GG.	Anaesthetic-induced malignant hyperpyrexia: a suggested method of treatment. British Medical Journal. 1971,3(5772):454-456.	South Africa	109	2.1	17.215	7.15
74	Litman RS, Rosenberg H.	Malignant hyperthermia: update on susceptibility testing. Jama. 2005,293(23):2918-2924.	United States	108	6.4	157.375	10.46
75	Brownell AK.	Malignant hyperthermia: relationship to other diseases. British Journal of Anaesthesia. 1988,60(3):303-308.	Canada	107	3.1	11.719	2.63
76	Treves S, Anderson AA, Ducreux S, Divet A, Bleunven C, Grasso C, Paesante S, Zorzato F.	Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscular Disorders. 2005,15(9-10):577-587.	Italy, Switzerland	106	6.2	3.538	0.86
77	Gronert GA, Milde JH, Theye RA.	Dantrolene in porcine malignant hyperthermia. Anesthesiology. 1976,44(6):488-495.	United States	106	2.3	9.198	2.84
78	Ellis FR, Keaney NP, Harriman DG, Sumner DW, Kyei-Mensah K, Tyrrell JH, Hargreaves JB, Parikh RK, Mulrooney PL.	Screening for malignant hyperpyrexia. British Medical Journal. 1972,3(5826):559-561.	England	106	2.1	17.215	7.15
79	Rosero EB, Adesanya AO, Timaran CH, Joshi GP.	Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009,110(1):89-94.	United States	101	7.8	9.198	2.84
80	Yang T, Riehl J, Esteve E, Matthaei KI, Goth S, Allen PD, Pessah IN, Lopez JR.	Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology. 2006,105(6):1164-1175.	United States, Australia, Vennezuela	101	6.3	9.198	2.84
81	Kalow W, Britt BA, Richter A.	The caffeine test of isolated human muscle in relation to malignant hyperthermia. Candian Anaesthetists Society Journal. 1977,24(6):678-694.	Canada	100	2.2	6.713	1.66
82	Iaizzo PA, Klein W, Lehmann-Horn F.	Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and	Germany	99	2.9	4.458	0.77

		malignant hyperthermia susceptible pigs. Pflugers archiv-European Journal of Physiology. 1988,411(6):648-653.					
83	Kobayashi S, Bannister ML, Gangopadhyay JP, Hamada T, Parness J, Ikemoto N.	Dantrolene stabilizes domain interactions within the ryanodine receptor. Journal of Biological Chemistry. 2005,280(8):6580-6587.	United States	98	5.8	5.458	0.91
84	Levitt RC, Nouri N, Jedlicka AE, McKusick VA, Marks AR, Shutack JG, Fletcher JE, Rosenberg H, Meyers DA.	Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics. 1991,11(3):543-547.	United States	98	3.2	4.31	1.21
85	Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, Nelson TE, Goldfarb LG.	Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology. 2005,102(3):515-521.	United States	96	5.6	9.198	2.84
86	Wappler F.	Malignant hyperthermia. European Journal of Anaesthesiology. 2001,18(10):632-652.	Germany	95	4.5	4.183	1.35
87	Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, Lehmann-Horn F.	Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Human Molecular Genetics. 1999,8(11):2055-2062.	Germany	94	4.1	5.121	1.12
88	Capacchione JF, Muldoon SM.	The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesthesia and Analgesia. 2009,109(4):1065-1069.	United States	92	7.1	6.627	1.95
89	Yang T, Ta TA, Pessah IN, Allen PD.	Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. Journal of Biological Chemistry. 2003,278(28):25722-25730.	United States	91	4.8	5.485	0.91
90	Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Roméro N, Mezin P, Bendahan D, Payen JF, Depret T, Maclennan DH, Lunardi J.	Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Human Mutation. 2005,26(5):413-425.	France, Canada, Italy	89	5.2	4.7	1.06
91	Snoeck M, van Engelen BG, Kusters B, Lammens M, Meijer R, Molenaar JP, Raaphorst J, Verschuuren-Bemelmans CC, Straathof CS, Sie LT, de Coo IF, van der Pol WL, de Visser M, Scheffer H, Treves S, Jungbluth H, Voermans NC, Kamsteeg EJ.	RYR1-related myopathies: a wide spectrum of phenotypes throughout life. European Journal of Neurology European Journal of Neurology. 2015,22(7):1094-1112.	Netherlands, Belgium, Switzerland, England	88	12.6	6.288	1.26

92	Harbitz I, Chowdhary B, Thomsen PD, Davies W, Kaufmann U, Kran S, Gustavsson I, Christensen K, Hauge JG.	Assignment of the porcine calcium release channel gene, a candidate for the malignant hyperthermia locus, to the 6p11----q21 segment of chromosome 6. Genomics. 1990,8(2):243-248.	Japan	88	2.8	4.31	1.21
93	Keating KE, Quane KA, Manning BM, Lehane M, Hartung E, Censier K, Urwyler A, Klausnitzer M, Muller CR, Heffron JJ, McCarthy TV.	Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Human Molecular Genetics. 1994,3(10):1855-1858.	Ireland, Switzerland, Germany	88	3.1	5.121	1.12
94	Ibarra M CA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi YK, Ochiai R, Nishino I.	Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology. 2006,104(6):1146-1154.	Japan	88	5.5	9.198	2.84
95	Strazis KP, Fox AW.	Malignant hyperthermia: a review of published cases. Anesthesia and Analgesia. 1993,77(2):297-304.	United States	87	3.0	6.627	1.95
96	Dainese M, Quarta M, Lyfenko AD, Paolini C, Canato M, Reggiani C, Dirksen RT, Protasi F.	Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice. Faseb Journal. 2009,23(6):1710-1720.	Italy, United States	86	6.6	5.834	0.98
97	Davis M, Brown R, Dickson A, Horton H, James D, Laing N, Marston R, Norgate M, Perlman D, Pollock N, Stowell K.	Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. British Journal of Anaesthesia. 2002,88(4):508-515.	Australia, New Zealand, England	86	4.3	11.719	2.63
98	Laver DR, Owen VJ, Junankar PR, Taske NL, Dulhunty AF, Lamb GD.	Reduced inhibitory effect of Mg^{2+} on ryanodine receptor-Ca^{2+} release channels in malignant hyperthermia. Biophysical Journal. 1997,73(4):1913-1924.	Australia	86	3.4	3.699	0.88
99	Nelson TE, Jones EW, Venable JH, Kerr DD.	Malignant hyperthermia of Poland China swine: studies of a myogenic etiology. Anesthesiology. 1972,36(1):52-56.	United States	86	1.7	9.198	2.84
100	Censier K, Urwyler A, Zorzato F, Treves S.	Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. Journal of Clinical Investigation. 1998,101(6):1233-1242.	Italy, Switzerland	84	3.5	19.477	3.93

ACR, annual citation rate; CNCI, category normalized citation impact; IF, impact factor; NA, not available.